Clinical Trial Update: Post Market Clinical Follow-up of CRT-DX Therapy With Lumax 640/740 HF-T

View source ↗

Summary

Post-market clinical follow-up of the Lumax 640/740 HF-T CRT-DX therapy completed in patients with atrial fibrillation and heart failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Heart Failure

Drugs mentioned

• Lumax 640/740 HF-T CRT-DX

Snippet

Sponsor: Biotronik SE & Co. KG | Conditions: Atrial Fibrillation, Heart Failure | Status: COMPLETED